These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 25074720

  • 1. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N, Jalilian AR, Khalaj A, Johari-Daha F, Yavari K, Sabzevari O, Khanchi AR, Akhlaghi M.
    Daru; 2014 Jul 29; 22(1):58. PubMed ID: 25074720
    [Abstract] [Full Text] [Related]

  • 2. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan 29; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 3. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
    Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke HR.
    Eur J Nucl Med Mol Imaging; 2009 Sep 29; 36(9):1443-52. PubMed ID: 19350237
    [Abstract] [Full Text] [Related]

  • 4. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
    Wojdowska W, Karczmarczyk U, Maurin M, Garnuszek P, Mikołajczak R.
    Curr Radiopharm; 2015 Sep 29; 8(1):62-8. PubMed ID: 25506704
    [Abstract] [Full Text] [Related]

  • 5. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
    Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS, Snehlata, Malhotra A.
    Indian J Med Res; 2014 Apr 29; 139(4):544-54. PubMed ID: 24927340
    [Abstract] [Full Text] [Related]

  • 6. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR, Raubitschek A, Shively JE.
    Bioconjug Chem; 1994 Apr 29; 5(6):565-76. PubMed ID: 7873659
    [Abstract] [Full Text] [Related]

  • 7. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.
    Bioconjug Chem; 1998 Apr 29; 9(6):773-82. PubMed ID: 9815172
    [Abstract] [Full Text] [Related]

  • 8. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
    Cooper MS, Ma MT, Sunassee K, Shaw KP, Williams JD, Paul RL, Donnelly PS, Blower PJ.
    Bioconjug Chem; 2012 May 16; 23(5):1029-39. PubMed ID: 22471317
    [Abstract] [Full Text] [Related]

  • 9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar 16; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec 16; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 11. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
    Gholipour N, Vakili A, Radfar E, Jalilian AR, Bahrami-Samani A, Shirvani-Arani S, Ghannadi-Maragheh M.
    J Cancer Res Ther; 2013 Dec 16; 9(2):199-204. PubMed ID: 23771358
    [Abstract] [Full Text] [Related]

  • 12. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
    Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR.
    Int J Oncol; 1999 Nov 16; 15(5):1017-25. PubMed ID: 10536187
    [Abstract] [Full Text] [Related]

  • 13. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.
    Cancer Biother Radiopharm; 2000 Feb 16; 15(1):15-29. PubMed ID: 10740649
    [Abstract] [Full Text] [Related]

  • 14. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
    Pnwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R, Mishra AK.
    Cancer Biol Ther; 2005 Aug 16; 4(8):854-60. PubMed ID: 16082184
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS, Children's Oncology Group.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [Abstract] [Full Text] [Related]

  • 16. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
    Witzig TE.
    Cancer Chemother Pharmacol; 2001 Aug 15; 48 Suppl 1():S91-5. PubMed ID: 11587375
    [Abstract] [Full Text] [Related]

  • 17. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
    Kameswaran M, Pandey U, Dash A, Samuel G, Venkatesh M.
    Indian J Med Res; 2016 Jan 15; 143(1):57-65. PubMed ID: 26997015
    [Abstract] [Full Text] [Related]

  • 18. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 15; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 19. Preparation of clinical-scale 177 Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation.
    Guleria M, Das T, Kumar C, Amirdhanayagam J, Sarma HD, Banerjee S.
    J Labelled Comp Radiopharm; 2017 May 15; 60(5):234-241. PubMed ID: 28181275
    [Abstract] [Full Text] [Related]

  • 20. Preparation and preliminary bioevaluation studies of 68 Ga-NOTA-rituximab fragments as radioimmunoscintigraphic agents for non-Hodgkin lymphoma.
    Suman SK, Kameswaran M, Pandey U, Sarma HD, Dash A.
    J Labelled Comp Radiopharm; 2019 Oct 15; 62(12):850-859. PubMed ID: 31461549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.